



## J. B. CHEMICALS & PHARMACEUTICALS LIMITED

**REGD. OFFICE:**

"NEELAM CENTRE", 'B' WING, 4TH FLR.,  
HIND CYCLE ROAD, WORLI,  
MUMBAI - 400 010.

GRAM : DOCTORS AID, MUMBAI.

PHONE : 022-3045 1500 / 3045 1200

FAX : 022-2493 0534 / 2493 9633

<http://www.uniquepharma.com>

StockExchange-NSE letters/MM:SA:348

January 25, 2012

National Stock Exchange of India Ltd.  
Exchange Plaza, 5<sup>th</sup> floor,  
Plot no.C/1, 'G' Block,  
Bandra Kurla Complex,  
Bandra (East), Mumbai 400 051

**Stock Symbol: JBCHEPHARM**

Dear Sir,


**Sub : Unaudited Financial Results for the quarter/ nine months ended on  
December 31, 2011.**

Enclosed please find unaudited financial results for the quarter/nine months ended on December 31, 2011. These financial results have been approved and taken on record by the board of directors at its meeting held today.

We request you to take the above on record.

Thanking you,

Yours faithfully,  
for J. B. Chemicals & Pharmaceuticals Limited

  
M. C. Mehta  
Company Secretary - General Manager

Encl: As above



# J. B. CHEMICALS & PHARMACEUTICALS LIMITED

## REGD. OFFICE:

"NEELAM CENTRE", 'B' WING, 4TH FLR.,  
HIND CYCLE ROAD, WORLI,  
MUMBAI - 400 030.

GRAM : DOCTORS AID, MUMBAI.

PHONE : 022-3045 1500 / 3045 1200

FAX : 022-2493 0534 / 2493 9633

http://www.uniquepharma.com

## STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31<sup>ST</sup> DECEMBER, 2011

(Rs.in Lakhs)

| SR. NO. | PARTICULARS                                                                               | QUARTER ENDED             |                           |                           | NINE MONTHS ENDED         |                           | YEAR ENDED              |
|---------|-------------------------------------------------------------------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|-------------------------|
|         |                                                                                           | 31/12/2011<br>(Unaudited) | 30/09/2011<br>(Unaudited) | 31/12/2010<br>(Unaudited) | 31/12/2011<br>(Unaudited) | 31/12/2010<br>(Unaudited) | 31/03/2011<br>(Audited) |
| 1       | a) Net Sales (Net of excise)                                                              | 14,955.91                 | 16,077.14                 | 21,667.77                 | 48,777.46                 | 60,868.88                 | 78,757.94               |
|         | b) Other Operating Income                                                                 | 587.95                    | 3,287.93                  | 548.04                    | 4,387.98                  | 1,415.52                  | 1,912.61                |
|         | <b>Total Income</b>                                                                       | <b>15,543.86</b>          | <b>19,365.07</b>          | <b>22,215.81</b>          | <b>53,165.44</b>          | <b>62,284.40</b>          | <b>80,670.55</b>        |
| 2       | Expenditure                                                                               |                           |                           |                           |                           |                           |                         |
|         | a) (Increase)/Decrease in Stock in Trade & WIP                                            | 420.22                    | 500.01                    | (898.94)                  | 1,162.50                  | (321.24)                  | (1,286.13)              |
|         | b) Consumption of Raw Materials                                                           | 4,877.16                  | 5,718.18                  | 5,999.03                  | 15,705.25                 | 15,780.39                 | 20,900.33               |
|         | c) Purchase of Traded Goods                                                               | 1,391.45                  | 1,322.75                  | 865.26                    | 4,102.87                  | 3,540.05                  | 4,691.52                |
|         | d) Employees Cost                                                                         | 2,257.89                  | 2,130.96                  | 3,422.20                  | 7,499.15                  | 8,823.34                  | 11,642.70               |
|         | e) Depreciation                                                                           | 562.94                    | 567.50                    | 602.30                    | 1,697.94                  | 1,697.30                  | 2,265.08                |
|         | f) Sales Promotion & Publicity                                                            | 587.37                    | 1,015.00                  | 3,356.41                  | 2,856.41                  | 7,554.04                  | 10,527.89               |
|         | g) Exchange Fluctuation Suffered (Gain)/Loss                                              | 1,039.10                  | (134.49)                  | (37.91)                   | 899.29                    | 216.85                    | 16.75                   |
|         | h) Other Expenditure                                                                      | 4,041.86                  | 4,301.91                  | 4,602.47                  | 12,212.55                 | 12,707.25                 | 17,234.34               |
|         | <b>Total</b>                                                                              | <b>15,177.99</b>          | <b>15,421.82</b>          | <b>17,910.82</b>          | <b>46,135.96</b>          | <b>49,997.98</b>          | <b>65,992.48</b>        |
| 3       | <b>Profit from operations before Other Income &amp; Interest (1-2)</b>                    | <b>365.87</b>             | <b>3,943.25</b>           | <b>4,304.99</b>           | <b>7,029.48</b>           | <b>12,286.42</b>          | <b>14,678.07</b>        |
| 4       | Other Income                                                                              | 624.15                    | 1,361.63                  | 140.85                    | 2,404.11                  | 378.01                    | 586.79                  |
| 5       | <b>Profit before Interest (3+4)</b>                                                       | <b>990.02</b>             | <b>5,304.88</b>           | <b>4,445.84</b>           | <b>9,433.59</b>           | <b>12,664.43</b>          | <b>15,264.86</b>        |
| 6       | Interest                                                                                  | 493.69                    | 186.34                    | 158.84                    | 860.69                    | 547.01                    | 737.30                  |
| 7       | <b>Profit after Interest but before Exchange Fluctuation Gain / (Loss) (5-6)</b>          | <b>496.33</b>             | <b>5,118.54</b>           | <b>4,287.00</b>           | <b>8,572.90</b>           | <b>12,117.42</b>          | <b>14,527.56</b>        |
| 8       | Exchange Fluctuation Gain / (Loss)                                                        | (2,326.90)                | (1,912.93)                | 304.43                    | (4,509.63)                | 194.80                    | (422.22)                |
| 9       | <b>Profit/(Loss) after Interest but before Exceptional Items (7-8)</b>                    | <b>(1,830.57)</b>         | <b>3,205.61</b>           | <b>4,591.43</b>           | <b>4,063.27</b>           | <b>12,312.22</b>          | <b>14,105.34</b>        |
| 10      | Exceptional Income (Net)                                                                  | 0.00                      | 76,059.34                 | -                         | 76,059.34                 | -                         | -                       |
| 11      | <b>Profit/(Loss) from Ordinary Activities Before Tax (9+10)</b>                           | <b>(1,830.57)</b>         | <b>79,264.95</b>          | <b>4,591.43</b>           | <b>80,122.61</b>          | <b>12,312.22</b>          | <b>14,105.34</b>        |
| 12      | <b>Tax Expenses :</b>                                                                     |                           |                           |                           |                           |                           |                         |
|         | Current Tax                                                                               | (1,371.00)                | 17,203.00                 | 918.00                    | 16,585.00                 | 2,462.00                  | 2,810.00                |
|         | MAT Credit Entitlement                                                                    | -                         | -                         | (70.00)                   | -                         | (410.00)                  | (550.00)                |
|         | Deferred Tax                                                                              | 57.31                     | 66.61                     | (68.89)                   | 154.23                    | (80.35)                   | 19.63                   |
|         | Short/(Excess) Provision for Taxation for prior year                                      | -                         | -                         | -                         | -                         | (2.34)                    | 6.25                    |
| 13      | <b>Profit/(Loss) from Ordinary Activities After Tax (11-12)</b>                           | <b>(516.88)</b>           | <b>61,995.34</b>          | <b>3,812.32</b>           | <b>63,383.38</b>          | <b>10,342.91</b>          | <b>11,819.46</b>        |
| 14      | Paid-up Equity Share Capital<br>(Face Value Rs. 2/- per share)                            | 1,694.15                  | 1,694.10                  | 1,689.92                  | 1,694.15                  | 1,689.92                  | 1,690.34                |
| 15      | Reserves (excluding Revaluation Reserve) as per balance sheet of previous accounting year | -                         | -                         | -                         | -                         | -                         | 69,637.93               |
| 16      | Earnings Per Share (EPS)                                                                  |                           |                           |                           |                           |                           |                         |
|         | a) Basic ( Not annualised)                                                                | (0.61)                    | 73.30                     | 4.52                      | 74.90                     | 12.25                     | 14.00                   |
|         | b) Diluted ( Not annualised)                                                              | (0.61)                    | 73.15                     | 4.51                      | 74.86                     | 12.23                     | 13.96                   |
| 17      | Public Shareholding                                                                       |                           |                           |                           |                           |                           |                         |
|         | No. of shares                                                                             | 37,853,210                | 37,850,710                | 37,642,460                | 37,853,210                | 37,642,460                | 37,663,735              |
|         | % of shareholding                                                                         | 44.69                     | 44.69                     | 44.55                     | 44.69                     | 44.55                     | 44.56                   |

# Unique



## J. B. CHEMICALS & PHARMACEUTICALS LIMITED

### REGD. OFFICE:

"NEELAM CENTRE", 'B' WING, 4TH FLR.,  
HIND CYCLE ROAD, WORLI,  
MUMBAI - 400 030.

GRAM : DOCTORS AID, MUMBAI.

PHONE : 022-3045 1500 / 3045 1200

FAX : 022-2493 0534 / 2493 9633

http://www.uniquepharma.com

|    |                                                                                  |            |            |            |            |            |            |
|----|----------------------------------------------------------------------------------|------------|------------|------------|------------|------------|------------|
| 18 | <b>Promoters and Promoter Group Shareholding</b>                                 |            |            |            |            |            |            |
|    | a) Pledged/Encumbered                                                            |            |            |            |            |            |            |
|    | Number of shares                                                                 | -          | -          | -          | -          | -          | -          |
|    | Percentage of shares (as a % of the shareholding of promoter and promoter group) | -          | -          | -          | -          | -          | -          |
|    | Percentage of shares (as a % of the total share capital of the company)          | -          | -          | -          | -          | -          | -          |
|    | b) Non-encumbered                                                                |            |            |            |            |            |            |
|    | Number of shares                                                                 | 46,854,090 | 46,854,090 | 46,853,590 | 46,854,090 | 46,853,590 | 46,853,090 |
|    | Percentage of shares (as a % of the shareholding of promoter and promoter group) | 100        | 100        | 100        | 100        | 100        | 100        |
|    | Percentage of shares (as a % of the total share capital of the company)          | 55.31      | 55.31      | 55.45      | 55.31      | 55.45      | 55.44      |

### NOTES :

1. The above financial results have been reviewed by the audit committee and approved by the board of directors at its meeting held on January 25, 2012.
2. The statutory auditors have carried out a limited review of the above unaudited financial results for the quarter and nine months ended on December 31, 2011.
3. The quarter continued to witness volatility in Rupee - US\$ rate movement. Consequently, the results for the quarter were significantly affected by exchange fluctuation loss (translation) provision of Rs.2326.90 Lacs made consequent to further weakening of Rupee during the quarter.
4. The figures for the previous quarter/nine months ended December, 2010, include figures of Russia-CIS OTC business, which has been divested during the year. Therefore, the figures are strictly not comparable.
5. There were no outstanding investor complaints at the beginning of the quarter. The company received 11 complaints from the investors during the quarter, which have been disposed of during the quarter.
6. The company is engaged in a single segment of activity namely, "Pharmaceuticals".
7. During the quarter, the company allotted 2,500 equity shares against exercise of stock options.
8. Previous quarter's / period's figures have been regrouped / re-stated, wherever necessary.

For J.B. CHEMICALS & PHARMACEUTICALS LTD.

Place : Mumbai  
Date : January 25, 2012

J.B. MODY  
CHAIRMAN & MANAGING DIRECTOR